Viking Therapeutics, Inc. Earnings

Viking Therapeutics, Inc.’s revenue fell -100% since last year same period to $0Mn in the Q4 2024. On a quarterly growth basis, Viking Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Viking Therapeutics, Inc.’s net profit fell -43.94% since last year same period to $-35.42Mn in the Q4 2024. On a quarterly growth basis, Viking Therapeutics, Inc. has generated -42.01% fall in its net profits since last 3-months.

Viking Therapeutics, Inc.’s net profit margin fell -Inf% since last year same period to -Inf% in the Q4 2024. On a quarterly growth basis, Viking Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Viking Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.31 - a -11.18% fall from last quarter’s estimates.

Viking Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.31.

Viking Therapeutics, Inc.’s earning per share (EPS) fell -57.69% since last year same period to -0.41 in the Q1 2025. This indicates that the Viking Therapeutics, Inc. has generated -57.69% annual rate of fall in its earning per share (EPS) in the last 4 quarters.